Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.

Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.

Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.

Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.

Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.

Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.

Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.

Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.

Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.

Abstract: A high-pressure fuel pump includes a drive shaft, and a vane pump and a plunger pump which are driven by the drive shaft. The vane pump is configured to supply pre-pressurized fuel to the plunger pump. The drive shaft includes a cam configured to drive a piston rod of the plunger pump such that the plunger pump alternately executes a fuel suction stroke and a fuel discharge stroke. The drive shaft further includes a shaft portion for driving a rotor of the vane pump. The vane pump is configured such that for each fuel suction stroke of the plunger pump the vane pump provides a fuel supply cycle that is advanced by a phase angle relative to the fuel suction stroke.

Abstract: A chimeric antigen receptor, containing a ligand binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain, the co-stimulatory domain containing CD94 and/or LT? intracellular regions. The present invention further relates to engineered immune cells containing such a chimeric antigen receptor, and uses thereof in the treatment of diseases, such as cancer, autoimmune diseases, and infections.

Abstract: Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition comprising the engineered immune cell and use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.

Abstract: Provided is an NK inhibitory molecule, which includes one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, wherein the NK inhibitory ligand specifically binds to NK inhibitory receptors to inhibit the killing of NK cells against the engineered immune cells expressing the NK inhibitory molecule. Also provided is an engineered immune cell expressing the NK inhibitory molecule of the present invention, wherein the expression of at least one MHC-related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of cancers, infections or autoimmune diseases. Compared to the traditional engineered immune cells, the engineered immune cell can significantly inhibit the killing effect of NK cells in a subject, thereby reducing the risk of HvGD.

Abstract: Embodiments of the present disclosure provide a method and system for training a model by using training data. The training data includes a plurality of samples, each sample includes N features, and features in the plurality of samples form N feature columns, and the method includes: determining an importance value of each of the N feature columns; determining whether the importance value of each of the N feature columns satisfies a threshold condition; performing a dimension reduction on M feature columns to generate P feature columns in response to the determination that the importance values of the M feature columns do not satisfy the threshold condition, wherein M<N and P<M; merging (N?M) feature columns having importance values that satisfy the threshold condition and the generated P feature columns to obtain (N?M+P) feature columns; and training the model based on the training data including the (N?M+P) feature columns.

Abstract: The present disclosure provides methods and an apparatuses for building a data identification model. One exemplary method for building a data identification model includes: performing logistic regression training using training samples to obtain a first model, the training samples comprising positive and negative samples; sampling the training samples proportionally to obtain a first training sample set; identifying the positive samples using the first model, and selecting a second training sample set from positive samples that have identification results after being identified using the first model; and performing Deep Neural Networks (DNN) training using the first training sample set and the second training sample set to obtain a final data identification model. The methods and the apparatuses of the present disclosure improve the stability of data identification models.

Abstract: Methods and apparatuses for training model based on random forest are provided. The method includes: dividing worker nodes into one or more groups; performing random sampling, by worker nodes in each group, in the preset sample data to obtain the target sample data; and training, by the worker nodes in each group, one or more decision tree objects using the target sample data. Example embodiments of the present disclosure do not need to scan the complete sample data for once, thereby greatly reducing the amount of data to be read, the time cost, and further the iterative update time of the model. The efficiency of training is improved.

Abstract: A high-pressure fuel pump includes a drive shaft, and a vane pump and a plunger pump which are driven by the drive shaft. The vane pump is configured to supply pre-pressurized fuel to the plunger pump. The drive shaft includes a cam configured to drive a piston rod of the plunger pump such that the plunger pump alternately executes a fuel suction stroke and a fuel discharge stroke. The drive shaft further includes a shaft portion for driving a rotor of the vane pump. The vane pump is configured such that for each fuel suction stroke of the plunger pump the vane pump provides a fuel supply cycle that is advanced by a phase angle relative to the fuel suction stroke.

Abstract: Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting Axl and BCL-2.

Abstract: The present disclosure provides feature data processing methods and devices. One exemplary feature data processing method comprises: classifying features into an important feature set and an auxiliary feature set according to information attribute values of the features; converting features in the auxiliary feature set to hash features; and combining the hash features with features in the important feature set, and setting the combined features as fingerprint features. Training and prediction of to-be-processed data can be performed based on the fingerprint features. With the embodiments of the present disclosure, training dimensions can be more controllable and the amount training data amount can be reduced. Therefore, the efficiency of data processing can be improved.